Aptose Biosciences Inc Stock Price Today (NSE: APS)
Fundamental Score
Aptose Biosciences Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aptose Biosciences Inc share price today is ₹266.00, down 1.54% on NSE/BSE as of 3 August 2026. Aptose Biosciences Inc (APS) is a Small-cap company in the Heavy Electrical Equipment sector with a market capitalisation of ₹591.59 (Cr). The 52-week high for APS share price is ₹543.95 and the 52-week low is ₹261.00. At a P/E ratio of 10.47x, APS is currently trading below its industry average P/E of 38.29x. The company has a Return on Equity (ROE) of 45.36% and a debt-to-equity ratio of 0.27.
Aptose Biosciences Inc Share Price Chart — NSE/BSE Historical Performance
Aptose Biosciences Inc share price chart: -9.08% return over the past month. 52-week high ₹543.95, 52-week low ₹261.00.
Aptose Biosciences Inc — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹270.40 | ₹275.00 | ₹269.25 | ₹270.95 | 18.75K (Cr) | |
| ₹276.55 | ₹278.80 | ₹272.25 | ₹273.35 | 26.75K (Cr) | |
| ₹279.00 | ₹280.50 | ₹274.90 | ₹277.70 | 22.25K (Cr) | |
| ₹275.45 | ₹285.00 | ₹274.75 | ₹279.25 | 9.00K (Cr) | |
| ₹278.95 | ₹282.80 | ₹274.00 | ₹275.45 | 12.00K (Cr) | |
| ₹280.00 | ₹282.95 | ₹277.00 | ₹278.95 | 14.25K (Cr) | |
| ₹282.00 | ₹288.20 | ₹278.60 | ₹279.95 | 20.25K (Cr) | |
| ₹290.55 | ₹293.95 | ₹282.00 | ₹285.75 | 15.25K (Cr) | |
| ₹295.35 | ₹302.55 | ₹292.00 | ₹293.45 | 11.00K (Cr) | |
| ₹300.00 | ₹306.75 | ₹300.00 | ₹300.40 | 15.50K (Cr) |
Aptose Biosciences Inc — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹298.00 | ₹306.95 | ₹269.25 | ₹270.95 | -9.08% | |
| ₹302.00 | ₹330.00 | ₹302.00 | ₹326.35 | +8.06% | |
| ₹372.90 | ₹374.85 | ₹328.00 | ₹329.85 | -11.54% | |
| ₹288.05 | ₹395.00 | ₹280.00 | ₹384.70 | +33.55% | |
| ₹295.00 | ₹309.80 | ₹261.00 | ₹264.50 | -10.34% | |
| ₹321.05 | ₹398.00 | ₹321.00 | ₹351.80 | +9.58% | |
| ₹366.25 | ₹371.95 | ₹300.00 | ₹323.95 | -11.55% | |
| ₹425.00 | ₹425.05 | ₹350.15 | ₹364.00 | -14.35% | |
| ₹483.50 | ₹483.50 | ₹442.30 | ₹444.35 | -8.10% | |
| ₹446.10 | ₹543.95 | ₹446.10 | ₹525.30 | +17.75% | |
| ₹470.70 | ₹504.00 | ₹442.20 | ₹450.80 | -4.23% | |
| ₹527.05 | ₹538.00 | ₹470.75 | ₹475.50 | -9.78% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Aptose is an M&A arbitrage play, but the risk-reward isn't compelling unless you believe the market is mispricing the deal's certainty.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Aptose Biosciences' shareholders approved the acquisition by Hanmi Pharmaceutical in a "go private" transaction on March 31, 2026. The shareholders also approved the continuance of the company from the Canada Business Corporations Act to the Business Corporations Act (Alberta). Aptose expects the arrangement to be completed by the end of April 2026, pending customary closing conditions and regulatory approvals. Under the terms of the agreement, Aptose shareholders will receive C$2.41 in cash per Common Share.
CORE STORY (THE REAL GAME)
- Shareholder approval secured
- Final court approval received
- Expected closing by end of April 2026
- Successful completion of acquisition by Hanmi
- Positive updates on TUS+VEN+AZA triplet therapy
- Regulatory approvals for the arrangement
- Deal closure risk
- Auditor's 'going concern' doubt
- Reliance on Hanmi for funding
FII decreased to 0.0% (Δ -0.79%), DII increased to 0.56% (Δ 0.45%). Unclear if this relates to the deal closing.
The heavy electrical equipment sector is seeing increased activity due to power capacity addition programs. However, Aptose is a biotech company, so this is irrelevant.
No - Free Cash Flow 5Y: ₹-5.45 Cr
Aptose's future hinges entirely on the Hanmi acquisition closing in the next few weeks. Post-acquisition, it will be a private entity focused on its oncology pipeline.
Primary Thesis Risk
Hanmi walks, stock craters.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aptose Biosciences Inc Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aptose Biosciences Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of APS across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (45.36%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (55.94%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 10.47 vs Industry: 38.29)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (43.96%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (56.24% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (99.24% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (17.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (72.62%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Weak Earnings Growth (-50.03% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-55.90 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.46%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Aptose Biosciences Inc vs Heavy Electrical Equipment Peers
Peer Comparison - Heavy Electrical Equipment
Compare Aptose Biosciences Inc with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
67/100 | ₹266.00₹266 | ₹591.59₹591.59 | 10.47Average 10.5 Average | 45.36%Excellent 45.36% Excellent | 55.94%Excellent 55.94% Excellent | 0.27Excellent 0.3 Excellent | 99.24%Excellent 99.24% Excellent | 56.24%Excellent 56.24% Excellent | 0.03% | |
ABB India LtdABB India Ltd... ABB • 500002 | 64.2/100 | ₹7284.50₹7285 | ₹152553.18₹152553.18 | 100.15Average 100.2 Average | 22.39%Excellent 22.39% Excellent | 29.93%Excellent 29.93% Excellent | 0.01Excellent 0.0 Excellent | 57.13%Excellent 57.13% Excellent | 17.80%Excellent 17.80% Excellent | 0.55% |
Hitachi Energy India LtdHitachi Energy ... POWERINDIA • 543187 | 72.8/100 | ₹32175.00₹32175 | ₹151500.72₹151500.72 | 147.39Average 147.4 Average | 21.89%Excellent 21.89% Excellent | 29.02%Excellent 29.02% Excellent | 0.02Excellent 0.0 Excellent | 53.66%Excellent 53.66% Excellent | 18.96%Excellent 18.96% Excellent | 0.02% |
CG Power and Industrial Solutions LimitedCG Power and In... CGPOWER • 500093 | 76.1/100 | ₹863.40₹863 | ₹146315.18₹146315.18 | 120.95Average 121.0 Average | 20.48%Excellent 20.48% Excellent | 26.71%Excellent 26.71% Excellent | 0.01Excellent 0.0 Excellent | 69.51%Excellent 69.51% Excellent | 33.18%Excellent 33.18% Excellent | 0.14% |
Bharat Heavy Electricals LtdBharat Heavy El... BHEL • 500103 | 63.1/100 | ₹407.00₹407 | ₹145514.83₹145514.83 | 91.87Average 91.9 Average | 6.23%Poor 6.23% Poor | 9.14%Poor 9.14% Poor | 0.31Excellent 0.3 Excellent | 20.93%Excellent 20.93% Excellent | 14.31%Good 14.31% Good | 0.33% |
Siemens LtdSiemens Ltd... SIEMENS • 500550 | 68.4/100 | ₹3760.00₹3760 | ₹127184.63₹127184.63 | 45.34Average 45.3 Average | 19.22%Good 19.22% Good | 21.44%Excellent 21.44% Excellent | 0.02Excellent 0.0 Excellent | 29.56%Excellent 29.56% Excellent | 20.09%Excellent 20.09% Excellent | 0.00% |
Siemens Energy India LtdSiemens Energy ... ENRIN • 544390 | 51.3/100 | ₹3230.80₹3231 | ₹124569.80₹124569.80 | 92.39Average 92.4 Average | 50.47%Excellent 50.47% Excellent | 67.75%Excellent 67.75% Excellent | 0.04Excellent 0.0 Excellent | — — | — — | 0.11% |
GE Vernova T&D India LtdGE Vernova T&D ... GVT&D • 522275 | 72/100 | ₹4323.30₹4323 | ₹120249.98₹120249.98 | 94.00Average 94.0 Average | 57.32%Excellent 57.32% Excellent | 76.43%Excellent 76.43% Excellent | 0.01Excellent 0.0 Excellent | 85.76%Excellent 85.76% Excellent | 12.45%Good 12.45% Good | 0.21% |
Suzlon Energy LtdSuzlon Energy L... SUZLON • 532667 | 64.4/100 | ₹48.01₹48 | ₹71461.81₹71461.81 | 22.59Average 22.6 Average | 40.64%Excellent 40.64% Excellent | 35.07%Excellent 35.07% Excellent | 0.06Excellent 0.1 Excellent | 45.66%Excellent 45.66% Excellent | 37.98%Excellent 37.98% Excellent | 0.00% |
Thermax LtdThermax Ltd... THERMAX • 500411 | 50/100 | ₹4306.00₹4306 | ₹54121.84₹54121.84 | 97.82Average 97.8 Average | 10.55%Average 10.55% Average | 13.94%Average 13.94% Average | 0.42Excellent 0.4 Excellent | 17.66%Excellent 17.66% Excellent | 17.59%Excellent 17.59% Excellent | 0.31% |
Schneider Electric Infrastructure LimitedSchneider Elect... SCHNEIDER • 534139 | 50.5/100 | ₹1355.30₹1355 | ₹32525.99₹32525.99 | 145.94Average 145.9 Average | 35.61%Excellent 35.61% Excellent | 29.63%Excellent 29.63% Excellent | 0.71Good 0.7 Good | 80.08%Excellent 80.08% Excellent | 17.38%Excellent 17.38% Excellent | 0.00% |
Top Heavy Electrical Equipment Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- ABB India Ltd share price152553.18 Cr
- Hitachi Energy India Ltd share price151500.72 Cr
- CG Power and Industrial Solutions Limited share price146315.18 Cr
- Bharat Heavy Electricals Ltd share price145514.83 Cr
- Siemens Ltd share price127184.63 Cr
Aptose Biosciences Inc Quarterly Performance
Latest quarterly metrics for APS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
43.96%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
8.94%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
56.24%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
99.24%
Compounded annual net profit growth over 5 years
Aptose Biosciences Inc Technical Indicators
SMA 50, SMA 200, RSI and volume signals for APS — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Aptose Biosciences Inc Financial Statements
Annual income statement, balance sheet and cash flow for Aptose Biosciences Inc (APS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Aptose Biosciences Inc
About APS (Aptose Biosciences Inc)
Aptose Biosciences Inc (APS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Heavy Electrical Equipment sector ...with a current market capitalisation of ₹591.59 (Cr). Aptose Biosciences Inc has delivered a Return on Equity (ROE) of 45.36% and a ROCE of 55.94%. The debt-to-equity ratio stands at 0.27, reflecting the company's capital structure. Investors tracking APS share price can monitor key metrics including P/E ratio, promoter holding of 72.62%, and quarterly earnings growth.
Company Details
APS Share Price: Frequently Asked Questions
What is the current share price of Aptose Biosciences Inc?
Aptose Biosciences Inc (APS) trades at ₹266.00 on NSE. Market cap ₹591.59 (Cr). Educational data only.
What is the P/E ratio of Aptose Biosciences Inc?
Aptose Biosciences Inc has a P/E of 10.47x vs industry average 38.29x.
What is the Bull Run score for Aptose Biosciences Inc?
Aptose Biosciences Inc has a Bull Run score of 67/100 based on 25+ financial parameters.
Does Aptose Biosciences Inc pay dividends?
Aptose Biosciences Inc has a dividend yield of 0.03%. Past dividends don't guarantee future payments.
What is the ROE of Aptose Biosciences Inc?
Aptose Biosciences Inc has ROE of 45.36%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aptose Biosciences Inc?
Aptose Biosciences Inc has debt-to-equity of 0.27.
Is Aptose Biosciences Inc a good investment?
Bull Run gives Aptose Biosciences Inc a score of 67/100. This is not investment advice — consult a SEBI-registered advisor.